Podcasts about Eli Lilly

Eli Lilly is escalating its fight against companies selling unapproved retatrutide — and this time, the lawsuits could have implications far beyond GLP-1s. Dave Crosland and Scott McNally break down what makes these lawsuits different and what they could mean for research chemical and peptide companies serving the bodybuilding world. Then we get into your questions on Dianabol and estrogen testing, Raloxifene vs. Tamoxifen, cycling with an enlarged prostate, insulin protocols, long-term low-dose Anavar, micro dosing Tren, Masteron and vision issues, and more. 0:00 Will Lilly & Retatrutide Change the Research Chem Market? 0:45 Support the Show 1:25 What the Eli Lilly Lawsuits Could Mean for Bodybuilding 7:45 Lilly Targets Shipping, Social Media & Payment Processing 10:00 Social Media Crackdowns on Steroid & Gear Talk 13:00 Craziest Pre-Workouts Ever 16:50 Does Dianabol Estrogen Show Up on a Standard E2 Test? 18:30 Raloxifene vs. Tamoxifen 20:00 Steroid Cycles With an Enlarged Prostate 24:00 Insulin Protocols: Dave vs. Scott 44:20 Vigorous Steve's Long-Term 5 mg Anavar Experiment 47:40 British Slang 52:00 Can 15–25 mg of Tren Per Week Do Anything? 53:45 Masteron & Vision Issues UK Blood Work Get your Labs done by Dave in the UK : https://evalbloodanalysis.com/home/ Support the Podcast Patreon — Help keep the show growing. Even $5/month makes a difference. https://www.patreon.com/thinkbigbodybuilding Sponsors TRUE NUTRITION — Custom supplements for serious lifters Use code THINK to save https://www.truenutrition.com/THINK STROM SPORTS — Performance supplements trusted by athletes UK: https://tinyurl.com/ydmbfa54 US: https://stromsportsus.com Supplement Source Canada — Top brand supplements with fast shipping http://www.supplementsource.ca Merch Official THINK BIG Merch — Train, represent, support the brand https://think-big.printify.me/products

Earnings calls are a chance to catch up with the latest developments across Big Pharma and beyond, and last quarter was no different. From the rollout of AI to the oral GLP-1 battle between Novo Nordisk and Eli Lilly and new leadership at Sarepta and Sanofi, it feels like the opportunities and challenges for biopharma have never been greater. In this week’s episode of "The Top Line," Fierce Pharma Senior Editor Fraiser Kansteiner and Fierce Biotech Senior Editor James Waldron share their takeaways from another whirlwind season of earnings calls. Alongside a Q2 scorecard breakdown, the Fierce editors discuss how several new CEOs are finding their footing, which drugs appear poised to cross the $1 billion sales threshold in 2026 and more. To learn more about the topics in this episode: Biopharma saw a Q2 sales boom led by Lilly, Sanofi, Regeneron and Astellas Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues Novo CEO has 'no doubt' on eventual share price recovery as Wegovy pill continues to wow Sarepta’s new CEO Michael Severino faces critical milestones to prove growth See omnystudio.com/listener for privacy information.

In der heutigen Folge sprechen die Finanzjournalisten Nando Sommerfeldt und Holger Zschäpitz über Broadcoms Schuldenplan, Georgs geniale Gas-Idee und die historischen Auswüchse am Anleihemarkt. Außerdem geht es um Walmart, Advance Auto Parts, AutoZone, O'Reilly Automotive, Home Depot, Lowe's, TJX Companies, Coty, JD Sports Fashion, Adidas, Puma, Fresenius, Fresenius Medical Care, Sartorius, UBS, Tonies, Korea Gas Corporation, Vontobel, Alibaba, Deere, Broadcom, Apollo Global Management, Blackstone, Goldman Sachs, Bank of America, Nvidia, Apple, Microsoft, Amazon, Alphabet, TSMC, Meta Platforms, Samsung Electronics, ASML, SK Hynix, Deutsche Börse, Moderna, BioNTech, Eli Lilly, Novo Nordisk, Mini Future Long auf den TTF-Gaspreis von Vontobel, (WKN: VY80G4), Vanguard FTSE Global All-Cap ETF thesaurierend (WKN: A42B1M), Vanguard FTSE Global All-Cap ETF ausschüttend (WKN: A42B1N), Vanguard FTSE Global Small-Cap ETF thesaurierend (WKN: A42B1P), Vanguard FTSE Global Small-Cap ETF ausschüttend (WKN: A42B1Q), Vanguard FTSE All-World ex-U.S. UCITS ETF thesaurierend (WKN: A42B1R), Vanguard FTSE All-World ex-U.S. ETF ausschüttend (WKN: A42B1S), SPDR MSCI ACWI IMI ETF (WKN: A1JJTD), Vanguard ESG Global All Cap ETF thesaurierend (WKN: A2QL8U), Vanguard FTSE All-World ETF thesaurierend (WKN: A2PKXG), Vanguard FTSE All-World ETF ausschüttend (WKN: A1JX52). Am 2. Oktober findet unser „Alles auf Aktien“-Summit in Berlin statt. Mit dem Code „AAAFRIENDS“ sparst du 50 Prozent auf dein Ticket – aber nur unter folgendem Link: https://veranstaltung.businessinsider.de/event/financesummit26/summary?rp=c6dc55d6-6f4f-4fb4-b75f-3f3501d84859 Wir freuen uns an Feedback über aaa@welt.de. Holt euch jetzt den exklusiven NordVPN-Deal inkl. 4 Bonusmonaten mit dem Code Allesaufaktien oder unter https://nordvpn.com/allesaufaktien Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Hier könnt ihr den AAA-Newsletter abonnieren: https://www.welt.de/newsletter/article232797673/Alles-auf-Aktien-Der-taegliche-Boersen-Newsletter-fuer-WELTplus-Abonnenten.html Und – ganz neu: AAA gibt es jetzt auch auf Instagram: https://www.instagram.com/alles_auf_aktien/ Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Anzeige: Eight Sleep: Der Pod 5 reguliert die Temperatur im Bett automatisch, trackt Schlaf- und Gesundheitswerte ohne Wearable und kann so zu besserem Schlaf beitragen. Mit dem Code ALLESAUFAKTIEN erhaltet ihr auf https://www.eightsleep.com/allesaufaktien bis zu 350 Euro Rabatt. Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Decentralized clinical Trials (DCTs) bring some or all elements of a clinical trial closer to patients. Consent, screening, treatment administration, and more can be administered through digital technologies and local health care providers, expanding accessibility for patients who face barriers to participation in traditional single site trials. In this episode, CANCER BUZZ speaks with Erin Pierce, MSN, APRN, FNP-C, Associate Clinical Investigator and Nurse Practitioner at HonorHealth Research Institute, and Kristen Kipping-Johnsson, MPH, Director of Network Research Operations at the University of Chicago, about how each of their cancer programs are approaching DCT implementation. Their discussion explores how decentralized components, such as community-based treatment delivery, centralized research infrastructure, and hybrid trial designs, can increase participation opportunities for patients in both community and academic settings. Guests: Erin Pierce, MSN, APRN, FNP-C Associate Clinical Investigator Nurse Practitioner HonorHealth Research Institute Scottsdale, AZ   Kristen Kipping-Johnson, MPH Director of Network Research Operations University of Chicago Chicago, IL "APPs are really poised to step into that role [of investigator] and help, not take the place of physicians, but work alongside our physician colleagues and enable us to expand the abilities of research." —Erin Pierce, MSN, APRN, FNP-C "Quality of life, being able to keep patients treated closer to home, allow them to stay with the physician that diagnosed them...Those are the things that are really important to me when it comes to decentralization." —Kristen Kipping-Johnson, MPH Resources HonorHealth Research Institute's First Steps to Approaching Decentralized Clinical Trials (DCTs) University of Chicago's Path to Operationalizing Decentralized Phase 1 Trials Across a Regional Network ACCC's Community Oncology Research Institute White Paper: Bringing Cancer Research to the Community:  Strategic Approaches to Representative Oncology Clinical Trial Design This podcast was created in partnership with the Decentralized Trials & Research Alliance, with support from Eli Lilly and Company, Gilead Sciences, and Merck.

On June 22, 2026, the Lymphoma Hub held a virtual symposium, titled Optimizing treatment for chronic lymphocytic leukemia with BTK inhibitors. During the symposium, Lymphoma Hub Steering Committee member Francesc Bosch, Vall d'Hebron Barcelona Hospital Campus, Barcelona, ES, led a case-based presentation and panel discussion featuring Susan O'Brien, Farrukh Awan, and Gilles Salles on optimizing chronic lymphocytic leukemia management in a changing landscape. This educational activity is independently supported by Eli Lilly and Company. All content is developed by the faculty in collaboration with SES. Funders are allowed no influence. Hosted on Acast. See acast.com/privacy for more information.

Alissa Coram and Ed Carson walk through Tuesday's market action and discuss key stocks to watch in Stock Market Today. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

August 14, 2026: Your daily rundown of health and wellness news, in under 5 minutes. Today's top stories: JG Wentworth survey finds 92% of US adults have delayed or abandoned medical care due to cost, creating an opening for lower-cost consumer health models Regenerative farming products hit $2B in annual US retail sales as 40 global food companies sign onto an initiative tying sourcing to soil health Eli Lilly files six lawsuits against sellers of unapproved retatrutide as CBP intercepts nearly 90,000 illicit GLP-1 vials in July alone Today's episode is brought to you by AIIR — a modern communications and experiential agency for health, wellness, fitness, and performance brands. From earned media to events and creator-led campaigns, AIIR helps companies sharpen their story, earn attention, and build trust that compounds. Visit https://aiir.agency to learn more. More from Fitt: Fitt Insider breaks down the convergence of fitness, wellness, and healthcare — and what it means for business, culture, and capital. Subscribe to our newsletter → insider.fitt.co/subscribe Work with our recruiting firm → https://talent.fitt.co/ Follow us on Instagram → https://www.instagram.com/fittinsider/ Follow us on LinkedIn → linkedin.com/company/fittinsider Reach out → insider@fitt.co

In der heutigen Folge sprechen die Finanzjournalisten Lea Oetjen und Philipp Vetter über den Kurssprung von Vestas, die neue Prognose von TKMS und ein pikantes Detail aus Norwegen. Außerdem geht es um CoreWeave, Meta, Super Micro Computer, Nebius, Rocky Mountain Chocolate, Lumentum, Cerebras Systems, StubHub, Cisco, Coherent, Infineon, Suss Microtec, Siltronic, Siemens Energy, Nordex, E.on, SpaceX, Tesla, Yum! Brands, Yum China, Wendy's, McDonald's, Restaurant Brands International, Cava Group, Sweetgreen, Chipotle, Novo Nordisk, Eli Lilly, Costco, Cooper Companies und Johnson & Johnson. Am 2. Oktober findet unser „Alles auf Aktien“-Summit in Berlin statt. Mit dem Code „AAAFRIENDS“ sparst du 50 Prozent auf dein Ticket – aber nur unter folgendem Link: https://veranstaltung.businessinsider.de/event/financesummit26/summary?rp=c6dc55d6-6f4f-4fb4-b75f-3f3501d84859 Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Hier könnt ihr den AAA-Newsletter abonnieren: https://www.welt.de/newsletter/article232797673/Alles-auf-Aktien-Der-taegliche-Boersen-Newsletter-fuer-WELTplus-Abonnenten.html Und – ganz neu: AAA gibt es jetzt auch auf Instagram: https://www.instagram.com/alles_auf_aktien/ Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

OnEaster Sunday in 2014, Christian Angermayer, the German investor, was on the beach on the Caribbean island of Canouan with three friends, contemplating whether he should take magic mushrooms.  Before he made his decision, he called a professor he knew who studies psychopharmacology. He explained to Angermayer that he was in the perfect set and setting, was of healthy mind, and he should try it.  So Angermayer, who says he feared he would end up freaking out and living as “a farmer in Argentina,” sprinkled some mushrooms in yogurt, ate it, and let the drugs take hold.  “I always say that I need to build a huge mushroom statue there,” says Angermayer, now 48 and worth $1.2 billion. “It was the most important positive experience of my life. When I came out [of the trip], although it took me years to get the thesis right, I had the first inclination that if it helped me this much as a happy healthy person, I can see the validation for how it can help people with mental health issues and beyond.”  Angermayer spent the next three years working on that thesis. On December 29, 2017, he took another trip, this time he came away with message from the divine: Go forward. There is no downside. By Will Yakowicz, Forbes Staff Learn more about your ad choices. Visit megaphone.fm/adchoices

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of compelling stories that underscore the dynamic shifts and groundbreaking progress within the industry. Recently, Akeso's ivonescimab received a landmark approval for first-line treatment of non-small cell lung cancer (NSCLC) in China. This marks a significant shift in China's regulatory environment, which is increasingly fostering innovative treatment options. Ivonescimab's approval not only enhances Akeso's standing in oncology but also provides new hope for NSCLC patients, a cancer type notoriously difficult to treat. In the arena of mergers and acquisitions, Alfasigma has strategically expanded its reach by acquiring key assets from Nordic Pharma. This acquisition opens doors to new therapeutic areas like arthritis, women's health, and critical care—an astute move to diversify offerings and enhance global market presence. Such strategic expansions are essential for companies aiming to maintain competitive edge and explore untapped markets. Eli Lilly has taken legal action against six U.S. companies involved in unauthorized sales of its experimental weight-loss drug, retatrutide. This highlights ongoing challenges in intellectual property protection, emphasizing the balance between innovation safeguarding and market expansion. The legal actions are part of broader efforts to preserve public safety and ensure proper distribution channels for groundbreaking therapies. On the quality control front, Fresenius faced a setback with the recall of a batch of Actemra biosimilars due to glass particle contamination concerns. This incident serves as a stark reminder of the critical role rigorous quality assurance plays in pharmaceutical manufacturing, especially as biosimilars gain traction for their cost-effectiveness and accessibility. In an intriguing blend of technology and healthcare, Samsung Electronics has secured FDA clearance for its Galaxy Buds earphones to function as over-the-counter hearing aids. This development illustrates the increasing convergence of consumer electronics with medical devices, offering innovative solutions to enhance accessibility in hearing health. Turning to psychedelic therapies, Definium Therapeutics reported significant success in its Phase 3 trials for an LSD-based formulation targeting generalized anxiety disorder. Building on earlier successes in depression studies, Definium is paving the way for psychedelic compounds in mainstream medicine. The results not only bolster confidence in such therapies but also signal a potential paradigm shift in treating mental health disorders. Moreover, Oracle Health has introduced an upgraded patient portal featuring an AI assistant designed to simplify medical records management and appointment scheduling. This advancement is part of a larger trend towards integrating artificial intelligence into healthcare systems to improve patient engagement and streamline processes, ultimately enhancing healthcare delivery efficiency. BridgeBio's ATTR stabilizer Attruby achieved impressive quarterly sales of $222 million, nearing blockbuster status as it captures significant market share in treating transthyretin amyloidosis (ATTR). This success underscores the growing importance of small molecule therapies in addressing complex cardiovascular conditions and reflects an industry trend towards stabilizer-first markets. InduPro has successfully raised $77 million in Series B funding supported by industry leaders like Sanofi and Lilly. The investment is set to propel their cancer pipeline forward with a focus on induced proximity and bispecific antibody platforms—innovations poised to revolutionize oncology treatment by enhancing drug specificity and efficacy. On the regulatory front, Chiesi UK's delayed-release mercaptamine received NHS endorsement for cystinosis treatment—an advancement that expands therapeutic options for patients requiring cystine-depleting therapy. Such regulatory support is crucial for facilitating access to innovative treatments for rare diseases. Amidst these developments, Gilead Sciences licensed MacroGenics' bispecific antibody program—a strategic move to bolster its oncology portfolio through milestone payments and royalties. This reflects a broader industry pattern where larger pharmaceutical companies seek pipeline diversification through strategic partnerships and acquisitions of innovative technologies. In vaccine development news, StablePharma's SPVX02 tetanus-diphtheria vaccine achieved promising Phase 1 results without refrigeration requirements—an innovation that could significantly enhance global vaccination efforts by overcoming cold chain distribution challenges. Finally, Insilico Medicine stands at the forefront of AI integration into drug discovery processes under CEO Alex Zhavoronkov's leadership. By promoting a 'fail-fast' approach at the Bio International Convention, Insilico aims to accelerate drug development timelines while reducing costs—a strategy indicative of biopharma's evolution towards more data-driven decision-making processes. These stories collectively highlight an era marked by rapid innovation within pharmaceuticals and biotech sectors. As companies navigate these complexities through scientific advancements and strategic maneuvers alike—there lies immense potential not only for enhancing patient care but also driving economic growth across global healthcare landscapes.Support the show

En el episodio de esta semana, Karla y René platican sobre el análisis de Grupo IUSA; el aumento en las vacantes para chief of staff; Eli Lilly and Company México y el crecimiento de Mounjaro; la popularidad de Candy Crush; y los viajes de Estados Unidos a Europa.Whitepaper Off The RecordRecomendaciones:London Falling: A Mysterious Death in a Gilded City and a Family's Search for Truth (English Edition)The End of Normal: A Wife's Anguish, A Widow's New LifeThe Mysterious Art of Conducting

It's been a busy week for tech giant Meta. Its new glasses have sparked controversy over privacy concerns, while founder Mark Zuckerberg published his AI manifesto, and the company indicated that it might be willing to pay local communities to host data centres in their areas. Irish Times tech expert Ciara O'Brien explains why the glasses have caused such a stir and how Zuckerberg's approach to AI differs.In part two: Ireland's corporation tax receipts are bulging, helped by the increase in the rate of tax paid by large companies as a result of recent changes agreed under the auspices of the OECD. The government recently published exchequer returns for the first seven months of the year, giving an insight into the extra corporation tax that is likely to flow our way. It's a helpful backdrop for the government in the run-up to October's budget. Eoin Burke-Kennedy looks at the numbers and what they mean. He also looks at what might happen to Ireland's public finances if an Apple, Microsoft, or Eli Lilly were to pull out.Brought to you in association with EY. Hosted on Acast. See acast.com/privacy for more information.

A practicing pathologist explains why DaVita, UnitedHealth, and Natera are playing fundamentally different games — and why one of them could break first.Investing in healthcare stocks requires a different framework than semiconductor investing. In this excerpt from a CSI live Q&A, we sit down with Dr. Brad Gibson — a practicing pathologist and private-practice partner — to break down how the US healthcare system actually gets paid, and what that means for stock picking.Brad walks through four investable buckets: medical service providers (DaVita, Natera, TransMedics), health insurers (UnitedHealth, CVS, Cigna, Elevance), pharmaceutical companies (Eli Lilly, Vertex), and healthcare hardware/software providers (Stryker, Veeva, Intuitive Surgical).The conversation covers Medicaid and Medicare reimbursement mechanics, CPT codes and RVU conversion factors, why private practices are being pushed into hospital consolidation, how pharmacy benefit managers generate profit through rebates, and why UnitedHealthcare's vertical integration has drawn regulatory scrutiny. Brad also gives his take on AI in pathology and drug discovery, and explains why he's more concerned about a healthcare cost bubble than an AI bubble.If you're building a healthcare investing thesis for 2026, this is where to start.If you want the reasoning behind more names like this one, Semiconductor Insider covers the process in more depth: https://www.chipstockinvestor.comAll our socials: https://linktr.ee/chipstockinvestorContent in this episode is for general information or entertainment only and is not specific or individual investment advice. Forecasts and information presented may not develop as predicted, and there is no guarantee any strategies presented will be successful. All investing involves risk, and you could lose some or all of your principal.

After two rejections, Replimune has made it across the regulatory finish line with its twice-rejected therapy for advanced melanoma. Meanwhile, the last of the major pharmas, including Eli Lilly and Novo Nordisk, reported second quarter earnings, and psychedelics made headlines once again.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today's episode delves into the latest innovations and strategic shifts propelling the industry forward. A notable dialogue emerging in psychiatric drug development comes from TLDR Biotech's engagement with Shlomi Raz and Ken Belotsky, co-founders of Palomar Labs. This conversation heralds a transformative shift in psychiatric treatments, moving beyond traditional psychedelics toward novel approaches deeply rooted in human experience. Initially inspired by the therapeutic potential of psychedelics such as psilocybin, early research, notably from Johns Hopkins, sought to establish these compounds within a biopharmaceutical framework. Despite historical evidence supporting their efficacy, challenges persisted in reclassifying these Schedule I substances as viable therapies. Raz and Belotsky, pioneers in this initial psychedelic wave, now lead efforts at Palomar Labs to develop next-generation therapeutics targeting serotonin receptors without the hallucinogenic effects typical of classical psychedelics. This approach seeks to dismantle longstanding industry biases against specific receptor targets known as "anti-targets." A critical concept in their methodology is "neuroplastogens," as popularized by David Olson at UC Davis. These compounds are believed to induce beneficial neuroplastic changes without causing hallucinations. However, Palomar Labs exercises caution, viewing neuroplasticity not as a definitive biomarker for therapeutic efficacy but rather as one of many aspects to consider. Their unconventional "reverse" drug development model begins with anecdotal human experiences and is validated backward through preclinical animal models before advancing to clinical trials. This method relies on overlooked data sources—such as discarded trial reports and traditional medicine use cases—to uncover therapeutic candidates traditionally ignored due to biases against certain receptor targets. For example, they explore therapies for Parkinson's disease bypassing direct dopamine receptor modulation and treatments for Alzheimer's-related aggression avoiding heavily sedative antipsychotics. Palomar Labs' venture studio model emphasizes disciplined capital allocation and an unbiased approach to research outcomes. By prioritizing drug candidates with strong evidence from human experiences, they aim to swiftly advance promising therapies to proof-of-concept stages, readying them for further development by pharmaceutical partners or venture-backed entities. This paradigm shift from target-centric development to a model grounded in empirical human data represents a significant advancement in psychiatric drug discovery. In other industry news, Replimune has successfully navigated regulatory hurdles to secure FDA approval for its melanoma therapy, Tudriqev, following two prior rejections. This achievement underscores the resilience required in drug development and strategic regulatory engagement. The approval highlights the potential of oncolytic virus therapies—Tudriqev employs an innovative approach by using viruses to selectively infect cancer cells while sparing healthy tissue, simultaneously stimulating an immune response. Meanwhile, Eli Lilly continues its dominance in the obesity treatment market with Zepbound, despite new oral competitors. The enduring preference for injectable solutions highlights established efficacy and safety profiles that continue to resonate with healthcare professionals. In China, TransThera has gained regulatory approval for a bile duct cancer treatment, marking a significant step forward for Chinese innovation in oncology. Such advancements not only diversify treatment options but also elevate China's status as a pivotal contributor to global drug development. Challenges persist across the sector, exemplified by Fresenius Kabi's recall of a mislabeled morphine lot due to overdose risks. This incident underscores the vital importance of stringent quality control measures essential for patient safety. The biopharmaceutical landscape also sees Takeda securing FDA approval for its first-in-class orexin receptor agonist targeting narcolepsy—a testament to innovative approaches addressing unmet needs in sleep disorders. Amidst these developments, BioMarin has opted to terminate its $270 million rare disease asset following unsatisfactory Phase 3 results. Such decisions highlight the inherent risks within drug development pipelines and underscore the necessity for strategic flexibility. Leadership changes are shaping corporate trajectories too; BioNTech's appointment of Guido Oelkers as CEO exemplifies this trend. His experience will likely drive strategic realignments crucial for navigating complex industry challenges. Finally, the industry's focus on digital transformation is evident through Bausch + Lomb's partnership with VerilyMe—a collaboration aimed at enhancing dry eye education via digital and AI technologies. These stories collectively embody the dynamic nature of the pharmaceutical and biotech industries—where regulatory achievements, strategic pivots, and technological advancements are continuously redefining therapeutic landscapes and enhancing patient care worldwide. As we continue navigating this rapidly evolving field, staying informed on these developments is crucial for leveraging opportunities and addressing challenges within this innovative sector.Support the show

https://www.otplinks.com

Eli Lilly raised its full-year outlook after strong demand for its diabetes and obesity treatments drove a major jump in revenue and profit.In this episode, we look at how GLP-1 drugs have become one of the most important growth engines in health care—and why the competition to own this market is only getting fiercer.The bigger story is what happens when one product category grows so fast that it reshapes an entire company's strategy, valuation, and future.Support the Show• Amazon picks: https://amzn.to/4fUGHEm• Amazon picks: https://amzn.to/4pUHt8Q• Amazon picks: https://amzn.to/45a4MC9• Need a website or app? https://hireawebteam.com• Support us on Patreon: https://www.patreon.com/c/StageZeroNews?view_as=patron&vanity=StageZeroNews• Subscribe on Supercast: https://clubelon.supercast.com/Disclosure: Amazon links may earn a commission from qualifying purchases.

Meta is keihard op de vingers getikt in New Mexico. Het moet van de rechter ruim een half miljard dollar betalen, omdat platformen als Instagram veel te verslavend zijn voor minderjarigen. Maar daar blijft het niet bij. Ook moet het ineens aan allerlei strenge regels voldoen. Regels die het voor Meta (en adverteerders) ineens een stuk minder leuk maken. Deze aflevering kijken we naar deze tegenvaller. Een tegenvaller die sowieso niet op zichzelf staat. Er komen nog heel veel rechtszaken aan in heel veel Amerikaanse staten. Waarvoor Meta zelf 'maar' 2,4 miljard dollar achter de hand heeft gezet. Is dat te weinig? We zoeken het uit. Kijken we ook of die strenge regels het bedrijf niet veel meer gaan kosten dan die miljardenboetes. De Czechoslovak Group (CSG) komt ook voorbij. Het defensiebedrijf kwam voor de tweede keer als Amsterdams beursbedrijf met de kwartaalcijfers. Cijfers die aanvankelijk goed werden ontvangen. Beleggers waren blij met de extra omzet, vooral door orders uit Azië. Al verdween dat enthousiasme in de middag ineens weer. Verder hebben we het deze aflevering over president Trump die poeslief is voor Fed-baas Kevin Warsh. Rente verlagen? Graag, maar Warsh gaat er zelf niet helemaal over. Aldus een opvallend milde Trump. Ook aandacht voor Philip Morris. Dat wordt op de vingers getikt vanwege hun AI-beleid. En je hoort over Volkswagen. De voorzitter van de RvC roept de ceo op om flink te bezuinigen. Te gast: Erik Mauritz van Trade Republic BNR Beurs is een journalistiek onafhankelijke productie, mede mogelijk gemaakt door Saxo. Over de makers: Jelle Maasbach is presentator van BNR Beurs en freelance financieel journalist. Zijn favoriete aandeel om over te praten is Disney, maar daar lijkt hij de enige in te zijn. Sinds de eerste uitzending van BNR Beurs is 'ie er bij. Maxim van Mil is presentator van BNR Beurs en journalist bij BNR, waar hij zich focust op de financiële markten en ontwikkelingen in de tech-wereld. Je krijgt hem het meest enthousiast als hij kan praten over ASML, of oer-Hollandse bedrijven zoals Ahold of ABN Amro. Jorik Simonides is presentator van BNR Beurs, economieredacteur en verslaggever bij BNR. Hij wordt er vooral blij van als het een keer níet over AI gaat. Je hoort hem ook in de BNR-podcast Moerdijk: dorp van de rekening. Milou Brand is presentator van BNR Beurs, freelance podcastmaker en columnist bij het Financieele Dagblad. Jochem Visser is presentator van BNR Beurs, maakt Beursnerd XL en is redacteur bij de podcast Onder Curatoren. Vraag hem naar obscure zaken op financiële markten en hij vertelt je waarom het eigenlijk nóg leuker is dan je al dacht. Over de podcast: Met BNR Beurs ga je altijd voorbereid de nieuwe beursdag in. We praten je in een kleine 25 minuten bij over alle laatste ontwikkelingen op de handelsvloer. We blijven niet alleen bij de AEX of Wall Street, maar vertellen je ook waar nog meer kansen liggen. En we houden het niet bij de cijfers, maar zoeken ook iedere dag voor je naar duiding van scherpe gasten en experts. Of je nu een ervaren belegger bent of net begint met je eerste stappen op de beurs, de podcast biedt waardevolle inzichten voor je beleggingsstrategie. Door de focus op zowel de korte termijn als de lange termijn, helpt BNR Beurs luisteraars om de ruis van de markt te scheiden van de essentie.See omnystudio.com/listener for privacy information.

Market update for Thursday August 6, 2026Check out the Public app for incredible investing tools and to support the show (LINK)Follow us on Instagram (@TheRundownDaily) for bonus content and instant reactions.In today's episode, Zaid covers:What the gold rally says about the dollar, bond yields and the FedDisney's earnings beat, powered by parks, streaming and Toy Story 5Eli Lilly's monster quarter as Mounjaro and Zepbound sales surgeDoorDash's DashPass growth and Sandisk's surprising post-earnings selloffWhy used electric vehicles are suddenly rising in value

In der heutigen Folge sprechen die Finanzjournalisten Daniel Eckert und Lea Oetjen über den Kurssprung von Shopify, Rekordzahlen bei Infineon und die Liebeserklärung von SpaceX an Nvidia. Außerdem geht es um SpaceX, AMD, Nvidia, Shopify, Etsy, Alphabet, Disney, Eli Lilly, Novo Nordisk, Booking Holdings, Fresenius, Infineon, Vonovia, DHL Group, Allianz, UOB (United Overseas Bank), Siemens Energy, Siemens, Siemens Healthineers, ams, McDonalds, SPDR MSCI ACWI IMI (WKN: A1JJTD), Amundi Prime All Country World (WKN: ETF151), iShares Core Global Aggregate Bond EUR Hedged (WKN: A2H6ZT), Vanguard Global Aggregate Bond EUR Hedged (WKN: A2PJZJ). Am 2. Oktober findet unser „Alles auf Aktien“-Summit in Berlin statt. Mit dem Code „AAAFRIENDS“ sparst du 50 Prozent auf dein Ticket – aber nur unter folgendem Link. Am 2. Oktober findet unser "Alles auf Aktien"-Summit in Berlin statt. Mit dem Code „AAAFRIENDS“ sparst du 50 Prozent auf dein Ticket – aber nur unter folgendem Link. https://veranstaltung.businessinsider.de/event/financesummit26/summary?rp=c6dc55d6-6f4f-4fb4-b75f-3f3501d84859 Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Hier könnt ihr den AAA-Newsletter abonnieren: https://www.welt.de/newsletter/article232797673/Alles-auf-Aktien-Der-taegliche-Boersen-Newsletter-fuer-WELTplus-Abonnenten.html Und – ganz neu: AAA gibt es jetzt auch auf Instagram: https://www.instagram.com/alles_auf_aktien/ Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Anzeige: Eight Sleep: Der Pod 5 reguliert die Temperatur im Bett automatisch, trackt Schlaf- und Gesundheitswerte ohne Wearable und kann so zu besserem Schlaf beitragen. Mit dem Code ALLESAUFAKTIEN erhaltet ihr auf https://www.eightsleep.com/allesaufaktien bis zu 350 Euro Rabatt. Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Unser Partner Scalable Capital ist der einzige Broker, den deine Familie zum Traden braucht. Bei Scalable Capital gibt's nämlich auch Kinderdepots. Alle weiteren Infos gibt's hier: scalable.capital/oaws. Musk setzt bei KI-Chips voll auf NVIDIA. SpaceX plant eigenen Mobilfunktarif, Telkos zittern. Infineon hat Rekord, Börse ist enttäuscht. Alphabet verliert Top-KI-Forscher. Eli Lilly schlägt Novo Nordisk. Shopify wächst krass. Aschenbrenner pusht Citadel. Disney (WKN: 855686) mit starken Zahlen, aber nur 14er KGV. Günstiger als Netflix, günstiger als im Schnitt der letzten Dekade. Doch 40 Mrd. $ Schulden und 40 Mrd. $ geplante Investments dämpfen das Bild. Hyperliquid macht 180 Mio. $ Umsatz im Quartal und kauft 90% der Gewinne als Token zurück. KGV von 33 liegt zwischen Nasdaq und Coinbase. Kann man Krypto-Protokolle wie Aktien bewerten? Diesen Podcast vom 06.08.2026, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung. Learn more about your ad choices. Visit megaphone.fm/adchoices

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the intricate web of scientific advancements, regulatory updates, and strategic maneuvers shaping the industry. Let's begin with Eli Lilly's impressive financial performance, clocking a record-breaking $23 billion in revenue for Q2 2023. This achievement, driven by the success of Mounjaro and Zepbound in metabolic diseases, underscores the competitive landscape of therapies targeting chronic conditions. However, the slower launch of Foundayo highlights ongoing challenges. Meanwhile, competition in obesity treatments is intensifying as Novo Nordisk's Wegovy continues to dominate despite new entrants like Eli Lilly's Foundayo. This scenario reflects growing patient preference for oral medications over injectables. Gilead Sciences' HIV prevention franchise has exceeded $1 billion in quarterly sales, reflecting an increasing reliance on effective small molecule therapies for infectious diseases. Gilead also remains a focal point with its HIV pre-exposure prophylaxis franchise reaching sales milestones amid legal victories defending their tenofovir-based treatments. These legal precedents could influence future innovation policies across the industry. Artificial intelligence continues to make waves in drug discovery and clinical trials. Icon's partnership with Anthropic aims to integrate AI capabilities to accelerate drug development timelines. Similarly, Phylo and Chugai Pharmaceutical are collaborating to optimize drug discovery workflows using advanced AI platforms. These collaborations highlight a strategic move towards enhancing efficiency in drug development processes. In oncology, Amplia Therapeutics and Eli Lilly are evaluating a combination therapy for non-small cell lung cancer, while Evexta Bio and Roche are exploring a joint study for metastatic breast cancer. These partnerships underscore the industry's focus on combination therapies and precision medicine to improve cancer treatment outcomes. Additionally, AstraZeneca's partnership with CSPC Pharmaceutical to enhance biologics manufacturing in China signifies the importance of localized production capabilities. On the regulatory front, Arrowhead Pharmaceuticals' acquisition of an FDA rare pediatric disease priority review voucher for Plozasiran represents a commitment to addressing unmet needs in rare diseases. This voucher could expedite new drug applications, potentially bringing life-saving treatments to patients more quickly. Despite these advancements, challenges persist. Novo Nordisk's Cagrisema failed to achieve its primary endpoint in a Phase 3 trial for type 2 diabetes, highlighting the complexities of developing combination therapies for metabolic disorders. Similarly, Eli Lilly's discontinuation of its Phase 1/2 trial for GBA1 gene therapy reflects the hurdles faced in advancing gene therapies. Looking at industry dynamics, Amgen's decision to discontinue its early-stage obesity drug signifies a strategic shift towards focusing on more promising pipeline candidates like Maritide. This move aligns with broader trends prioritizing candidates with significant potential impact on patient care. Amgen's 'Repatha' is experiencing renewed interest due to positive cardiovascular risk reduction data, showcasing how robust clinical results can rejuvenate existing products. In regulatory news, Merck's 'Lipfendra' has been spotlighted by the FDA as part of its Complex New Product Validation pilot program. This positions Lipfendra as a potential game-changer in the PCSK9 inhibitor category. Lastly, financial maneuvers such as Attovia Therapeutics' $289 million IPO and Expedition Therapeutics' $115 million Series B funding highlight investor confidence in novel therapeutic areas like dermatological and respiratory treatments. The pharmaceutical landscape remains dynamic with Johnson & Johnson investing heavily in gene therapy ventures like Sail Biomedicines for CAR-T therapies. Meanwhile, regulatory challenges persist as seen with Capricor's cell therapy setback due to statistical complexities during FDA reviews. Despite setbacks faced by some companies, innovations continue to thrive. The launch of personalized genetic therapy centers signals a shift towards individualized medicine while research into safer CAR-T therapies progresses. In conclusion, these developments reflect an industry driven by innovation amidst regulatory challenges and strategic adjustments. As companies navigate this evolving landscape, their decisions will shape future healthcare innovations and patient care outcomes. Thank you for joining us on Pharma Daily; stay tuned for more insights from the world of pharmaceuticals and biotech.Support the show

P.M. Edition for Aug. 5. Seven-year-old Whatnot is gaining popularity among people drawn to its high-energy live auction sales on everything from fashion to trading cards. But as WSJ retail reporter Hanna Krueger discusses, some users say they're hooked even when they feel like they should walk away. Plus, progressive candidate Abdul El-Sayed clinched the Democratic senate nomination in a closely-watched race in Michigan. We hear from Journal reporter Terell Wright about what this means for the Democratic party's future. And Google shakes up the leadership of its AI operations as it struggles to keep pace with competitors' top models. Alex Ossola hosts. Whatnot, the Live Shopping App Where Some People Bid Until They're Broke  Sign up for the WSJ's free What's News newsletter. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Plus: Disney's third-quarter revenue was boosted by theme park visitors and Toy Story 5. And Eli Lilly posted higher revenue on continued GLP-1 demand. Alex Ossola hosts. Sign up for WSJ's free What's News newsletter. An artificial-intelligence tool assisted in the making of this episode by creating summaries that were based on Wall Street Journal reporting and reviewed and adapted by an editor. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Carl Quintanilla, Jim Cramer and David Faber drilled down on SpaceX's first quarterly report since going public. Shares of Elon Musk's company tumbled as a surge in AI spending overshadowed a Q2 beat. The anchors reacted to Musk outlining his trillion-dollar revenue forecast for SpaceX and saying the company will "exclusively" use Nvidia AI chips. The Nvidia news helped to send AMD shares sharply lower despite that company's better-than-expected quarterly results. Hear how AMD CEO Lisa Su reacted to it all in an exclusive interview. Also in focus:  The Dow and S&P 500 hit new all-time intraday highs; Eli Lilly and Disney jump on earnings beats; "Faber Report" on the Paramount-Warner Bros. Discovery antitrust trial set for March 2027.   Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Psychedelics can expand your consciousness in a way most people can't imagine. My guest is Dr. Chloe West, a PhD neuroscientist who's been researching psychedelics for nearly a decade and is now writing a book on psychedelics and religious trauma. Dr. Chloe explains what happens in the brain during a trip, from increased entropy to disorganized activity in the default mode network. Her framing of the brain as clay, where plasticity softens it, and the trip itself guides how it gets reshaped, is one of the clearest explanations I've heard. We get into the REBUS model and one finding that stopped me: the research doesn't actually show that psychedelics reliably turn atheists into believers, even though people will swear otherwise. Beliefs about the self, however, are another story. Her personal story is where this conversation deepens. Chloe grew up in evangelical Christianity in the South, walked away from it in graduate school, and is now researching how psychedelics might offer something the deconstruction space has been missing: a tool for reconstruction. She describes someone close to her who spent years praying out of fear, and after psychedelics only wanted to pray out of gratitude. That single shift, from fear to gratitude, is what many therapeutic outcomes seem to rest on. You'll learn: [0:00] Introduction [3:41] Psychedelics as the fastest method for rewiring rigid beliefs [7:57] Defining consciousness, and whether psychedelics can really expand it [17:30] Predictive processing turns your brain into a protection machine working against you [23:08] Why integration matters and how set and setting predict a bad trip [27:33] Eli Lilly's $3.8 billion DMT bet and why both political sides embrace psychedelics [37:49] Growing up evangelical and using psychedelics to heal religious trauma [50:21] Microdosing versus heroic doses, and the new psychedelics that skip the trip [57:32] Finding your default state of consciousness through silent retreats and breathwork [1:05:56] Which psychedelic calls to Chloe most, and the mystery of ayahuasca's plant intelligence Resources Mentioned: Sky Breath Meditation | Website Art of Living Retreat Center | Website For weekly essays on psychedelics, consciousness, and belief, join Dr. Chloe West's Substack here, or follow her on social media to stay connected. Find more from Dr. Chloe: Dr. Chloe West | Instagram | LinkedIn | Facebook | X | TikTok | YouTube | Substack Find more from Ste: Ste Lane | Instagram Radical Health Radio | Instagram | YouTube Heart and Soil Supplements | Website | Instagram | X | YouTube

Andrew, Ben, and Tom discuss SpaceX falling 11% despite laying out an ambitious AI and Starlink roadmap including Grok 5 trained on internal SpaceX data by year-end, 1.4GW of current compute growing toward 10GW by end of 2027, deploying NVL72-designed data centers on the ground rather than in space, boots on the moon by 2028, and the goal of scaling launch cadence to one per day in 2027, SpaceX's decision to go exclusively with Nvidia sending AMD down 9% despite good results and CPU acceleration while Arista Networks jumped 14% on accelerating networking demand tied to Nvidia, CVS raising guidance and re-adding Zepbound to its formulary while publicly backing Eli Lilly with expanded GLP-1 support, Lilly beating on stronger-than-expected GLP-1 pricing, Disney rising 4% on parks strength and a TikTok short-form video partnership, Uber slipping despite record first-time user additions, and the JOLTS report showing softer job openings but likely not a signal Warsh will weigh.Join our live YouTube stream Monday through Friday at 8:30 AM EST:http://www.youtube.com/@TheMorningMarketBriefingPlease see disclosures:https://www.narwhal.com/disclosure

Today we had the pleasure of hosting Corey Rosenbusch for a wide-ranging discussion on the fertilizer industry, global energy markets, and the geopolitical forces increasingly shaping both. Corey is the President and CEO of The Fertilizer Institute (TFI), headquartered in Arlington, Virginia. Corey joined TFI in 2020 after serving as President and CEO of the Global Cold Chain Alliance. He currently serves as Chair of the Texas A&M University Agricultural Leadership, Education & Communication Department Advisory Board and the Association Leadership Group. We were thrilled to host Corey to better understand the connections between fertilizer, natural gas, food security, and global supply chains. In our conversation, Corey provides a comprehensive overview of the global fertilizer industry and its critical connection to energy markets. He explains how natural gas serves as the essential feedstock for nitrogen fertilizer production, outlines the distinct dynamics of nitrogen, phosphate, potash, and sulfur markets, and discusses why fertilizer has become increasingly intertwined with global geopolitics, food security, and national security. We examine how disruptions in the Strait of Hormuz affected global flows of urea, ammonia, phosphate, and sulfur, why export restrictions from China and Russia have reshaped global trade, and how government subsidies, tariffs, and state-owned enterprises continue to influence fertilizer pricing and availability. Corey highlights the concentration of global fertilizer production and exports across a handful of countries and explains how those supply chains have become increasingly vulnerable to geopolitical disruption. Corey shares why current fertilizer market conditions differ from the 2022 Russia-Ukraine disruption, how weak farm economics and higher input costs are impacting U.S. growers, and why fertilizer prices are ultimately driven by global supply and demand rather than local production. We discuss the outlook for fertilizer demand, key Farm Bill provisions, including E15 and biostimulants, the competitiveness of U.S. fertilizer manufacturing, and why expanding domestic production, streamlining permitting, and maintaining access to affordable natural gas will be critical to strengthening both U.S. food security and energy security. We learned a great deal from Corey and greatly enjoyed the discussion. To start the show, Mike Bradley noted the day's market trifecta: lower bond yields, lower oil prices, and higher equity markets. The 10-year Treasury yield was trading between 4.60% and 4.65%, well below last week's high of ~4.75%. The Dow Jones Industrial Average (DJIA) was up approximately 1,000 points, driven largely by significant share price gains in Caterpillar and Goldman Sachs. These two stocks alone accounted for roughly 500 points of the DJIA's gain. He highlighted several companies scheduled to report second-quarter earnings results this week, including AMD, Disney, Eli Lilly, and SpaceX. On the oil market front, he noted that WTI crude oil prices had fallen roughly $9/bbl to ~$75-$76/bbl so far this week following a temporary pause in U.S. military strikes on Iran. While U.S. strikes are on hold for now, military action could resume at any point, contributing to heightened oil price volatility. Despite WTI declining more than 10% this week, the energy sector was down only ~1.5%. Investor focus last week was primarily on second-quarter earnings results from the U.S. integrated oil majors, Chevron and ExxonMobil, as well as refiners, with management teams indicating that global refining margins remain structurally tight. He highlighted BP's new CEO's comment that it would be "prudent" to stop thinking of BP as a traditional Big Oil supermajor and instead compete within its own weight class. He concluded by highlighting President Trump's remarks about to Chevron's and ExxonMobil's record-setting quarterly results. President Trump argued that these companies were making too much money and should return more of their profits to the public and lower retail prices. Chevron and ExxonMobil generated average second-quarter profit margins in the mid-to-high teens and have generally reported high single-digit to low-double-digit profit margins over the past three years. By comparison, large-cap tech companies reported average second-quarter profit margins of ~40% and have averaged ~45% to 50% profit margins over the last three years. Jeff Tillery added his perspective on the outlook for U.S. natural gas demand, noting that forecasts call for roughly 20 bcfd of cumulative demand growth over the next five years. While significant, he emphasized that this largely represents a continuation of trends already underway. U.S. natural gas demand increased by nearly 20 bcfd over the past five years, driven primarily by LNG exports, and he expects exports to remain the primary driver of growth going forward. While he remains constructive on the long-term natural gas demand outlook, he emphasized that the next phase is more evolutionary than transformational. 

The latest in business, financial, and market news and how it impacts your money, reported by CNBC's Peter Schacknow Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

US President Trump said they are moving along very nicely regarding Iran, and we will know in 48 hours about Iran.Axios reported that the proposed deal would route inbound Gulf traffic through Iranian waters and outbound traffic through Omani waters for 60 days, with no fees and the central lane cleared of mines within 30 days ahead of a permanent arrangement.Yemen's Houthis said they attacked a vessel in the Red Sea, attacked a Saudi oil tanker off the Yanbu and stated operations will continue and escalate in targeting Saudi oil tankers.US equity futures are mixed, with AMD and SPCX weighing on the NQ.DXY flat, NZD underperforms after weak employment data.Energy benchmarks climb as markets await for a potential agreement over the Strait of Hormuz.Looking ahead, highlights include US ADP Employment Change (Jul), S&P Services/Composite PMI Final (Jul), ISM Services PMI (Jul), NBH Minutes (Jul), US Treasury QRA/Press Conference, BCB Policy Announcement (Aug). Speakers include Fed's Cook. Earnings from Eli Lilly, Uber, Walt Disney & SanDisk.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

US President Trump said they are moving along very nicely regarding Iran, and we will know in 48 hours about Iran.US is nearing a Hormuz deal and is aiming for an announcement on Wednesday, according to Axios.Axios reported that the proposed deal would route inbound Gulf traffic through Iranian waters and outbound traffic through Omani waters for 60 days, with no fees and the central lane cleared of mines within 30 days ahead of a permanent arrangement.Crude futures remained pressured overnight after sliding yesterday as multiple reports pointed towards progress surrounding the reopening of the Strait of Hormuz.APAC stocks were mostly higher as the region took its cue from the rally on Wall Street; European equity futures indicate a positive cash market open.Looking ahead, highlights include Global S&P Services/Composite PMI Final (Jul), US ADP Employment Change (Jul), ISM Services PMI (Jul), NBH Minutes (Jul), US Treasury QRA/Press Conference, BCB Policy Announcement (Aug). Speakers include Fed's Cook & Schmid. Supply from Australia & Germany. Earnings from Eli Lilly, Uber, Walt Disney, SanDisk, Siemens Energy, Infineon, Deutsche Post, Glencore & Novo Nordisk.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

Alissa Coram and Ken Shreve walk through Wednesday's market action with key stocks to watch in Stock Market Today. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

En el episodio de hoy Valentina Orduz y Juan Manuel de los Reyes revisaron el trimestre récord de AMD, impulsado por la fuerte demanda de chips para centros de datos e IA, y las dudas sobre si podrá sostener ese ritmo sin sacrificar rentabilidad. Repasaron los números de SpaceX, con Starlink superando los 12 millones de suscriptores y un gasto en inversión que se disparó por su apuesta en IA, además del vencimiento del período de bloqueo que podría presionar la acción. Cerraron con Eli Lilly, la farmacéutica más valiosa del mundo, cuya estrategia de bajar precios para llegar a más pacientes elevó las ventas y las expectativas para el resto del año.

SpaceX on the move in after-hours trading on the back of its first earnings report since going public. Can investors expect SpaceX to blast off, or will the aerospace giant sink even further below its IPO price?Then, major Pharma earnings from giants like Pfizer and Merck beating Wall Street estimates with Amgen and Eli Lilly on deck. Founder and CEO of Portal Innovations John Flavin lays out the best trades in the Pharma market, and his reaction to Novo Nordisk's slide after disappointing guidance. Plus, why Morgan Stanley is bearish on AMD, digging into Caterpillar earnings, and can McDonald's make a comeback? Fast Money Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Today, a look at the broad market in a positive mood as recent divergences between AI hardware and other names were nowhere in evidence. We zoom in on Palantir's incredible quarterly reports and the wild and entertaining earnings call with CEO Alex Karp, wonder how SpaceX can deliver anything notable today relative to the company's valuation, and preview AMD, Novo Nordisk and Eli Lilly, all with Saxo Equity Strategist Ruben Dalfovo. Macro and FX and more also on today's pod, which was hosted by Saxo Global Head of Macro Strategy John J. Hardy. Links Yesterday's John J. Hardy substack post with many links, including on AI. John's The FX Trader piece from this morning, focusing especially on the recent coordinated JPY intervention and EURJPY. 69 Starship launches to get one decent payload to the moon? A Starship skeptic speaks out on concerns related to the idea of SpaceX using these space-based depots of fuel to extend the operating range of Starship.  Arnaud Bertrand challenges Palantir's AI Sovereignty framework, although Palantir's results spoke quite loudly late yesterday, as did CEO Alex Karp himself. Tungsten as an indicator of war risk and once again, a mineral supply chain that China dominates. About twice per week (in normal times, hopefully soon to resume), you will find links discussed on the podcast and a chart-of-the-day over at the John J. Hardy substack. Read daily in-depth market updates from the Saxo Market Call and the Saxo Strategy Team here. Please reach out to us at marketcall@saxobank.com for feedback and questions. Click here to open an account with Saxo. Intro music by AShamaluevMusic DISCLAIMER This content is marketing material. Trading financial instruments carries risks. Always ensure that you understand these risks before trading. This material does not contain investment advice or an encouragement to invest in a particular manner. Historic performance is not a guarantee of future results. The instrument(s) referenced in this content may be issued by a partner, from whom Saxo Bank A/S receives promotional fees, payment or retrocessions. While Saxo may receive compensation from these partnerships, all content is created with the aim of providing clients with valuable information and options.  

Novo Nordisk has spent years warning patients, regulators, lawmakers, and courts about the risks of synthetic semaglutide. Now, as patents begin to expire and China's pharmaceutical industry becomes increasingly important, Novo may be staring at a very uncomfortable question: what happens if synthetic semaglutide suddenly makes sense when Novo is the one making it?In this week's episode of The Weekly Dose, I dig into Novo's long-running recombinant-versus-synthetic semaglutide argument, the lawsuits and FDA petitions built around it, and a clip from more than 16 months ago showing that we were covering this exact issue long before it became part of the mainstream conversation. Novo Warned Us About Synthetic Semaglutide_ Now This_.txtWe also break down Pfizer's decision to kill two clinical-stage obesity drugs, including an oral GLP-1 acquired through its $10 billion Metsera deal, the strange science behind GIP receptor antagonism, and why Pfizer's remaining obesity pipeline still deserves attention. Plus, Wall Street is looking at Eli Lilly's obesity-fueled rally and asking just how big this market can get.In this episode:00:00 Novo's synthetic semaglutide problem02:00 VoaFit sponsor message03:30 The 16-month-old On The Pen receipt05:00 Recombinant vs. synthetic semaglutide07:00 Novo's FDA, legal, and political strategy09:00 Pfizer kills two obesity drugs11:00 What happened to Metsera's oral pipeline?13:00 The GIP agonist vs. antagonist paradox15:00 Why China matters to Pfizer and Novo17:00 Could Novo eventually make synthetic semaglutide?18:30 What comes next for Lilly, Novo, and PfizerThe big question: If Novo Nordisk eventually launches its own synthetically manufactured semaglutide, does that change how you view the arguments it has made against compounded semaglutide over the last several years?Comment below. I want to know where you land.More obesity medicine news and analysis: OnThePen.comAll my links, socials, and resources: linktr.ee/manonthemounjaroThis episode is sponsored by VoaFit. Learn more at voafit.com/otp.#GLP1 #Semaglutide #Ozempic #Wegovy #NovoNordisk #CompoundedSemaglutide #ObesityMedicine #Pfizer #EliLilly #Mounjaro #Zepbound #Metsera

This week, we're bringing you an episode of WSJ's Take On the Week. Host Telis Demos and guest host Spencer Jakab, investing columnist and writer of the Markets A.M. newsletter, are joined by Kaitlin Hendrix, asset allocation research director at Dimensional Fund Advisors, to decode investors' surging interest in private markets. They break down how investors may already have exposure in their investment portfolios to private companies like Anthropic, Stripe and Flipkart, through holdings in companies like Alphabet's Google, Amazon and Nvidia. Hendrix explains why your public index fund might already provide the diversification you're looking for, without the high fees. Plus, Jakab explains the way that big tech's private company investments are boosting earnings to near-unprecedented levels.  To watch the video version of this episode, visit our WSJ Podcasts YouTube channel or the video page of WSJ.com Sign up for the WSJ's free What's News newsletter. Further Reading:  Earnings Forecasts Are on Steroids For more coverage of the markets and your investments, head to WSJ.com, WSJ's Heard on The Street Column, and WSJ's Live Markets blog. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

As Anthony Fauci's stardom comes crashing to earth and more people realize how dirty and dangerous "Mr. Science" has been, we reduce his Wiki "about me" page to just one word: Disgraced. Florida seems ready to launch a criminal investigation against the good doctor as we learn about the financial incentives Fauci likely had to push a mass vaccination campaign. What was his take on the new vaccine company that Eli Lilly just bought for $1.5B? Stephen A Smith apologizes to NBA star Kyrie Irving who refused the jab and was dragged endlessly for it. Oh, Stephen.  

How do you bring AI into an organisation without losing what's made it work for 150 years? In this episode of the Digital HR Leaders podcast, David Green is joined by Eric Dozier, Executive Vice President and Chief People Officer at Eli Lilly, to explore what it takes for HR to lead AI and workforce transformation at enterprise scale. Join them, as they discuss: Why HR has to transform twice over in the AI era, first as a function, then as an organisation What prompted Lilly's AI journey, and how the friction points that came up shaped the approach going forward How the role of the manager is changing as AI becomes part of everyday work What separates AI capability from simply increased AI usage The principles guiding Lilly's approach to responsible AI, including where it supports leadership judgement and where it shouldn't How employee feedback has reshaped Lilly's AI strategy, and what Eric believes HR leaders should prioritise as they lead their own transformations This episode is sponsored by Valence. Nadia, Valence's AI coaching platform, connects talent strategy to the work employees are actually doing — offering coaching from the frontline to the boardroom, and surfacing organisational insights that weren't visible before. As the most widely deployed coach in the Fortune 500, Nadia is already helping global leaders like Nestlé, Delta, CVS, and Kraft Heinz transform talent at scale. Learn more at valence.co/insight222 Hosted on Acast. See acast.com/privacy for more information.

Psychedelic Therapy for Mental Health: Research, Safety, and the Path to FDA Approval: Dr. Will Van Derveer and Keith Kurlander, co-authors of “Psychedelic Therapy: A Revolutionary Approach to Restoring Your Mental Health and Reclaiming Your Life,” reveal the shift from recreational psychedelics to structured, research-based psychedelic-assisted therapy for conditions like PTSD, depression, and anxiety. Van Derveer describes limitations of conventional psychiatry (citing STAR*D remission rates) and his entry into MDMA-assisted PTSD research after promising results. They contrast controlled clinical protocols—screening, preparation, safe setting, trained facilitation, medical monitoring, and post-session integration—with uncontained recreational use. The discussion covers current policy momentum under Trump and RFK Jr., VA interest for veterans, and key agents: ketamine (including abuse risks and clinic-only Spravato), MDMA (phase 3 but not approved in 2024), psilocybin (phase 3, potential FDA approval), LSD (GAD trials), ibogaine (arrhythmia risk, Mexico clinics), ayahuasca, peyote, and microdosing. They also note commercialization, including Eli Lilly's acquisition of a 5-MeO-DMT nasal spray developer, and emphasize an integrative “all-of-the-above” mental health approach.

The traders talking all things Intel after the company's second quarter earnings, and what the results mean for the broader tech trade. Then, what a yield spike means for the economy ahead of the July Fed meeting next week. Chief economist at Ernst & Young Greg Daco lays out why investors should not expect a rate hike at the Fed meeting, and what Fed policy could look like in the second half. Plus, Brent topping $100 a barrel on the back of Iran tensions, data on Eli Lilly's newest GLP-1, and Google and Tesla plummeting on the back of earnings. Fast Money Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

As cyclosporiasis cases continue to rise, HHS Sec. Robert F. Kennedy Jr. insists the federal government has outbreaks “under control.” New Jersey Gov. Mikie Sherrill reveals that thousands of non-citizens were added to the voter rolls after a DMV glitch. And Novo Nordisk sues fellow obesity drugmaker Eli Lilly over a critical ad.  Learn more about your ad choices. Visit podcastchoices.com/adchoices

The Ukrainian President Volodymyr Zelensky has fired his army commander-in-chief, Oleksandr Syrskyi, in one of the biggest shake-ups of the country's military leadership since the start of Russia's full-scale invasion. General Syrskyi had clashed with the popular defence minister, Mykhailo Fedorov, whose own removal from office last week triggered rare mass protests in Ukraine. Also: France becomes the first country in the EU to ban children under the age of 15 from using social media. A special report from the school in Iran where 156 people, mostly children, were killed at the start of the US-Israeli war. As Venezuela's ousted leader Nicolás Maduro is due back in court in New York, Venezuelans tell the BBC they are too focused on trying to rebuild their lives after the earthquakes to give much thought to the criminal proceedings. The maker of Wegovy and Ozempic, Novo Nordisk, has launched legal action against its rival Eli Lilly, accusing it of false advertising in suggesting its weight-loss drugs perform better. Animal welfare experts in Britain are looking after a marmoset monkey that was found abandoned in a laundry bag on a London bus. And we look at the new developments in sleep health technology focusing on disease prediction.The Global News Podcast brings you the breaking news you need to hear, as it happens. Listen for the latest headlines and current affairs from around the world. Politics, economics, climate, business, technology, health – we cover it all with expert analysis and insight. Get the news that matters, delivered twice a day on weekdays and daily at weekends, plus special bonus episodes reacting to urgent breaking stories. Follow or subscribe now and never miss a moment. Get in touch: globalpodcast@bbc.co.ukPhoto: Ukraine's President Zelensky and now former Commander in Chief of the Ukrainian Armed Forces, Colonel General Oleksandr Syrskyi, visit an exhibition of new Ukrainian made drone-missiles Peklo in Kyiv. Credit: REUTERS/Valentyn Ogirenko

A new Gemini model is out and the AI world isn't impressed. But is this Alphabet knowing its business better than anyone else or a loss of the company's magic? Plus, we discuss Novo Nordisk suing Eli Lilly and GE Vernova's stock falling after a great earnings report. Travis Hoium, Lou Whiteman, and Jon Quast discuss: - Gemini's Model Dud? - Gemini Pro Delay - Novo Sues Eli Lilly - Novo's Desperation - GE Vernova Earnings - Energy's Peak Companies discussed: GE Vernova (GEV), Alphabet (GOOG), Novo Nordisk (NVO), Eli Lilly (LLY). Host: Travis Hoium Guests: Lou Whiteman, Jon Quast Engineer: Dan Boyd Disclosure: Advertisements are sponsored content and provided for informational purposes only. The Motley Fool and its affiliates (collectively, “TMF”) do not endorse, recommend, or verify the accuracy or completeness of the statements made within advertisements. TMF is not involved in the offer, sale, or solicitation of any securities advertised herein and makes no representations regarding the suitability, or risks associated with any investment opportunity presented. Investors should conduct their own due diligence and consult with legal, tax, and financial advisors before making any investment decisions. TMF assumes no responsibility for any losses or damages arising from this advertisement. We're committed to transparency: All personal opinions in advertisements from Fools are their own. The product advertised in this episode was loaned to TMF and was returned after a test period or the product advertised in this episode was purchased by TMF. Advertiser has paid for the sponsorship of this episode. Learn more about your ad choices. Visit ⁠⁠⁠megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices

#894: Miami is now more expensive than New York City. Novo Nordisk and Eli Lilly are battling it out over weight-loss ads. A new flip phone is coming and it's designed to minimize distractions by eliminating touchscreens and social media. The Big Boy train, the largest operating steam locomotive, is making its way across America to celebrate America 250. Finally, Substack is using AI to detect AI on its platform. Got difficult questions? Head to https://www.claude.ai/mbd to answer them.  Get tickets for our trivia tournament! https://caveat.nyc/events/the-morning-brew-trivia-tournament-2026-07-30  Grab tickets to our Performance Revue show! https://www.morningbrew.com/events/brew-performance-revue-2026?utm_campaign=performance_revue_2026&utm_source=mbd Subscribe to Morning Brew Daily for more of the news you need to start your day. Share the show with a friend, and leave us a review on your favorite podcast app. Listen to Morning Brew Daily Here:⁠ ⁠⁠https://www.swap.fm/l/mbd-note⁠⁠⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

This week on Market Mondays, we break down the biggest stories shaping the markets and answer the investing questions everyone is asking.We discuss whether DRAM has finally bottomed, if Micron's pullback is an opportunity, when gold could become a buy again, and why Apple and Eli Lilly continue to outperform. We also examine Oracle, SpaceX, Netflix, McDonald's, and the stocks we'd hold for the next 10–15 years.We also cover trading strategy, market bottoms, futures trading, portfolio construction, oil prices, AI competition from China's Kimi K3 model, and the biggest investing lessons of the year. Plus, MG The Mortgage Guy joins us to break down the latest in real estate, mortgages, housing affordability, interest rates, and what buyers and investors should be watching in today's market.If you're serious about building long-term wealth through investing and real estate, this is an episode you don't want to miss.#MarketMondays #Investing #StockMarket #RealEstate #MGTheMortgageGuy #IanDunlap #EarnYourLeisure #Stocks #WealthBuilding #Finance #Trading #Gold #Micron #SpaceX #Apple #OracleAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

P.M. Edition for July 21. Recent AI models from China claim they're just as powerful as some of the most cutting-edge models from OpenAI and Anthropic. Journal reporter Amrith Ramkumar joins to discuss the latest reactions from Silicon Valley and the White House. Plus, General Motors had a strong second quarter as consumers kept buying pickup trucks and SUVs. And New Jersey says a software error led to almost 400 non-citizens voting in elections in the state since 2023. Alex Ossola hosts. Sign up for the WSJ's free What's News newsletter. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Plus: Novo Nordisk files a deceptive advertising lawsuit against Eli Lilly. And the latest Chinese AI model launches rattle expectations for the biggest AI players in the US. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Chalene Johnson breaks down retatrutide, the peptide everyone is calling a GLP-3 and an Ozempic killer, cutting through the hype to get to what the science actually says. Eli Lilly's own clinical trials show weight loss results that beat anything semaglutide or tirzepatide has produced, but retatrutide is not FDA approved and is not legally available at any US pharmacy, which means almost nobody buying it online is actually getting the real thing. Chalene explains what retatrutide actually is (a triple agonist that adds glucagon receptor activity to the GLP-1 and GIP receptors already targeted by Ozempic, Wegovy, Mounjaro, and Zepbound), walks through what the phase three trial data really shows versus how it is being exaggerated online, and shares why an independent lab test of vials sold through TikTok, med spas, and Reddit found most contained only 7 to 14 percent of anything resembling the real molecule. She also unpacks the muscle preservation claims that are not backed by human data, the anhedonia and placebo effect reports circulating online, why bariatric surgery comparisons need context, and how to find a reputable source like Midi Health for anyone considering a GLP-1 through legitimate medical channels. Topics discussed: retatrutide, Ozempic, semaglutide, Wegovy, tirzepatide, Mounjaro, Zepbound, GLP-1, GLP-3, Eli Lilly, bariatric surgery, Midi Health, anhedonia, muscle wasting, peptides, BPC 157 Go Beyond The Podcast Join Chalene on her private podcast